Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02560558 · ClinicalTrials.gov registry record · Phase 4
Bela 8 Week Dosing
A Phase 4 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 166
- Enrollment target
NCT02560558 is a Phase 4 study that has completed, run by Emory University. The registered enrollment target is 166 participants.
The verdict
NCT02560558, a Phase 4 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 166 participants
- Enrollment target
Study Summary
The purpose of this study is to transition patients who have been stable on Belatacept for one year after kidney transplant from standard 4-week to an investigational 8-week belatacept dosing schedule. The investigators hypothesize that renal function and acute rejection rates will be non-inferior with 8-week belatacept dosing.
Interventions
- DRUG Belatacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2015-09 |
| Est. Completion | 2019-08-29 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02560558
The ClinicalTrials.gov registry entry for NCT02560558 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 166 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Belatacept is the first listed.
NCT02560558 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02560558 about?
NCT02560558 is a clinical study titled "Bela 8 Week Dosing". The purpose of this study is to transition patients who have been stable on Belatacept for one year after kidney transplant from standard 4-week to an investigational 8-week belatacept dosing schedule. The investigators hypothesize that renal function and acute rejection rates will be non-inferior w...
What is the current status of trial NCT02560558?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 166 participants. The study started on 2015-09. Estimated completion is 2019-08-29.
What interventions are being tested in trial NCT02560558?
The interventions under investigation include: Belatacept (DRUG).
Who is sponsoring clinical trial NCT02560558?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.